SavedAdd your journal

Journals / Turkish Journal of Gastroenterology / 2016 / Cilt: 27 - Sayı: 1

Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies

Ali Murat KAHVECİ
Veysel TAHAN
Pages
89–90
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

KAHVECİ, A. M., TAHAN, V. (2016). Daclatasvir plus sofosbuvir regimen sheds promising light on future hepatitis C virus genotype 3 therapies. Turkish Journal of Gastroenterology, Cilt: 27 - Sayı: 1, 89–90. https://ajindex.com/articles/410746

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (4)

  1. Tahan V. Are we hopefully very close to the end of HCV? Turk J Gastroenterol 2014; 25: 230-1
  2. McCombs J, Matsuda T, Tonnu-Mihara I, et al. The risk of long-term morbidity and mortality in patients with chronic hepa-titis C: results from an analysis of data from a department of veterans affairs clinical registry. JAMA Intern Med 2014; 174: 204-12
  3. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127-35
  4. Hézode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritapre-vir plus ritonavir with or without ribavirin in treatment-naive andtreatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 2015; 385: 2502-9.